Clinical trial
Use of Risk Factors for Initiation Therapy With Beacopp or Escalated Beacopp and Interim Evaluation and Modification of Therapy Based on Scintigraphy Results.
NCT00305149 is registered in ClinicalTrials.gov with Rambam Health Care Campus as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Use of Risk Factors for Initiation Therapy With Beacopp or Escalated Beacopp and Interim Evaluation and Modification of Therapy Based on Scintigraphy Results.
- Lead sponsor
- Rambam Health Care Campus
- Phase
- Not applicable
- Overall status
- Completed
- Start date
- July 31, 1999
- Completion date
- December 31, 2005
- Enrollment
- 130
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
classical hodgkin lymphoma, lymphocyte depletion, lymphocyte rich, mixed cellularity, nodular sclerosis